First Time Loading...

Cardiff Oncology Inc
NASDAQ:CRDF

Watchlist Manager
Cardiff Oncology Inc Logo
Cardiff Oncology Inc
NASDAQ:CRDF
Watchlist
Price: 3.99 USD -4.55% Market Closed
Updated: Apr 26, 2024

Intrinsic Value

CRDF's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. [ Read More ]

The intrinsic value of one CRDF stock under the Base Case scenario is 0.07 USD. Compared to the current market price of 3.99 USD, Cardiff Oncology Inc is Overvalued by 98%.

Key Points:
CRDF Intrinsic Value
Base Case
0.07 USD
Overvaluation 98%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Cardiff Oncology Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling CRDF stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Cardiff Oncology Inc

Provide an overview of the primary business activities
of Cardiff Oncology Inc.

What unique competitive advantages
does Cardiff Oncology Inc hold over its rivals?

What risks and challenges
does Cardiff Oncology Inc face in the near future?

Has there been any significant insider trading activity
in Cardiff Oncology Inc recently?

Summarize the latest earnings call
of Cardiff Oncology Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Cardiff Oncology Inc.

Provide P/S
for Cardiff Oncology Inc.

Provide P/E
for Cardiff Oncology Inc.

Provide P/OCF
for Cardiff Oncology Inc.

Provide P/FCFE
for Cardiff Oncology Inc.

Provide P/B
for Cardiff Oncology Inc.

Provide EV/S
for Cardiff Oncology Inc.

Provide EV/GP
for Cardiff Oncology Inc.

Provide EV/EBITDA
for Cardiff Oncology Inc.

Provide EV/EBIT
for Cardiff Oncology Inc.

Provide EV/OCF
for Cardiff Oncology Inc.

Provide EV/FCFF
for Cardiff Oncology Inc.

Provide EV/IC
for Cardiff Oncology Inc.

Show me price targets
for Cardiff Oncology Inc made by professional analysts.

What are the Revenue projections
for Cardiff Oncology Inc?

How accurate were the past Revenue estimates
for Cardiff Oncology Inc?

What are the Net Income projections
for Cardiff Oncology Inc?

How accurate were the past Net Income estimates
for Cardiff Oncology Inc?

What are the EPS projections
for Cardiff Oncology Inc?

How accurate were the past EPS estimates
for Cardiff Oncology Inc?

What are the EBIT projections
for Cardiff Oncology Inc?

How accurate were the past EBIT estimates
for Cardiff Oncology Inc?

Compare the revenue forecasts
for Cardiff Oncology Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Cardiff Oncology Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Cardiff Oncology Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Cardiff Oncology Inc compared to its peers.

Compare the P/E ratios
of Cardiff Oncology Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Cardiff Oncology Inc with its peers.

Analyze the financial leverage
of Cardiff Oncology Inc compared to its main competitors.

Show all profitability ratios
for Cardiff Oncology Inc.

Provide ROE
for Cardiff Oncology Inc.

Provide ROA
for Cardiff Oncology Inc.

Provide ROIC
for Cardiff Oncology Inc.

Provide ROCE
for Cardiff Oncology Inc.

Provide Gross Margin
for Cardiff Oncology Inc.

Provide Operating Margin
for Cardiff Oncology Inc.

Provide Net Margin
for Cardiff Oncology Inc.

Provide FCF Margin
for Cardiff Oncology Inc.

Show all solvency ratios
for Cardiff Oncology Inc.

Provide D/E Ratio
for Cardiff Oncology Inc.

Provide D/A Ratio
for Cardiff Oncology Inc.

Provide Interest Coverage Ratio
for Cardiff Oncology Inc.

Provide Altman Z-Score Ratio
for Cardiff Oncology Inc.

Provide Quick Ratio
for Cardiff Oncology Inc.

Provide Current Ratio
for Cardiff Oncology Inc.

Provide Cash Ratio
for Cardiff Oncology Inc.

What is the historical Revenue growth
over the last 5 years for Cardiff Oncology Inc?

What is the historical Net Income growth
over the last 5 years for Cardiff Oncology Inc?

What is the current Free Cash Flow
of Cardiff Oncology Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Cardiff Oncology Inc.

Financials

Balance Sheet Decomposition
Cardiff Oncology Inc

Current Assets 77.4m
Cash & Short-Term Investments 74.8m
Receivables 288k
Other Current Assets 2.3m
Non-Current Assets 4.2m
PP&E 2.9m
Other Non-Current Assets 1.3m
Current Liabilities 10.4m
Accounts Payable 2m
Accrued Liabilities 8.5m
Non-Current Liabilities 1.5m
Other Non-Current Liabilities 1.5m
Efficiency

Earnings Waterfall
Cardiff Oncology Inc

Revenue
488k USD
Operating Expenses
-45.9m USD
Operating Income
-45.4m USD
Other Expenses
3.9m USD
Net Income
-41.5m USD

Free Cash Flow Analysis
Cardiff Oncology Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

CRDF Profitability Score
Profitability Due Diligence

Cardiff Oncology Inc's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

ROIC is Increasing
Positive 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
Declining ROE
22/100
Profitability
Score

Cardiff Oncology Inc's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

CRDF Solvency Score
Solvency Due Diligence

Cardiff Oncology Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
61/100
Solvency
Score

Cardiff Oncology Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CRDF Price Targets Summary
Cardiff Oncology Inc

Wall Street analysts forecast CRDF stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CRDF is 10.71 USD with a low forecast of 7.07 USD and a high forecast of 14.7 USD.

Lowest
Price Target
7.07 USD
77% Upside
Average
Price Target
10.71 USD
168% Upside
Highest
Price Target
14.7 USD
268% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

CRDF Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

CRDF Price
Cardiff Oncology Inc

1M 1M
-26%
6M 6M
+287%
1Y 1Y
+159%
3Y 3Y
-57%
5Y 5Y
+17%
10Y 10Y
-99%
Annual Price Range
3.99
52w Low
0.96
52w High
5.91
Price Metrics
Average Annual Return 276.66%
Standard Deviation of Annual Returns 689.19%
Max Drawdown -96%
Shares Statistics
Market Capitalization 178.3m USD
Shares Outstanding 44 677 200
Percentage of Shares Shorted 7.86%

CRDF Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Cardiff Oncology Inc Logo
Cardiff Oncology Inc

Country

United States of America

Industry

Biotechnology

Market Cap

178.3m USD

Dividend Yield

0%

Description

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company is headquartered in San Diego, California and currently employs 22 full-time employees. The company went IPO on 2004-07-27. The firm is focused on developing treatment for cancer patients. Its drug candidate onvansertib, is a polo-like kinase 1 (PLK1) adenosine triphosphate (ATP) competitive inhibitor with the combination of chemotherapy and targeted therapeutics. Its clinical trial includes TROV-054, CRDF-001 and TROV-053. TROV-054 is a Phase I b/2 open-label clinical trial of onvansertib in combination with FOLFIRI (folinic acid, fluorouracil, and irinotecan) and Avastin (bevacizumab). TROV-053 is a Phase II open-label clinical trial of onvansertib in combination with Zytiga (abiraterone acetate)/prednisone. CRDF-001 is a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan, leucovorin, and fluorouracil for second line treatment of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).

Contact

CALIFORNIA
San Diego
11055 Flintkote Ave
+18589527570.0
https://cardiffoncology.com/

IPO

2004-07-27

Employees

22

Officers

CEO & Director
Dr. Mark Erlander Ph.D.
Chief Financial Officer
Mr. James E. Levine
Chief Scientific Officer?
Dr. Tod Smeal Ph.D.
VP of Finance & Administration
Ms. Elizabeth Anderson
Senior Vice President of Finance
Ms. Brigitte Lindsay
Senior VP of Regulatory Affairs
Mr. Charles Monahan R.Ph.
Show More
Chief Medical Officer
Dr. Fairooz Kabbinavar FACP, M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one CRDF stock?

The intrinsic value of one CRDF stock under the Base Case scenario is 0.07 USD.

Is CRDF stock undervalued or overvalued?

Compared to the current market price of 3.99 USD, Cardiff Oncology Inc is Overvalued by 98%.